| 1.31 0 (0%) | 05-01 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.9  |
1-year : | 2.33 |
| Resists | First : | 1.63 |
Second : | 2 |
| Pivot price | 1.34 |
|||
| Supports | First : | 1.03 |
Second : | 0.86 |
| MAs | MA(5) : | 1.37 |
MA(20) : | 1.38 |
| MA(100) : | 0.9 |
MA(250) : | 1.05 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 50.8 |
D(3) : | 57.1 |
| RSI | RSI(14): 50.6 | |||
| 52-week | High : | 2 | Low : | 0.47 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ IMNN ] has closed above bottom band by 43.5%. Bollinger Bands are 13.2% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.33 - 1.34 | 1.34 - 1.35 |
| Low: | 1.24 - 1.25 | 1.25 - 1.26 |
| Close: | 1.3 - 1.31 | 1.31 - 1.32 |
Imunon, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. Its product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, which is in development stage for various cancer indications. The company also has two feasibility stage platform technologies for the development of nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. The company was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. Imunon, Inc. was founded in 1982 and is based in Lawrenceville, New Jersey.
Thu, 25 Apr 2024
Imunon (NASDAQ:IMNN) Trading Down 2.3% - Defense World
Thu, 18 Apr 2024
IMUNON's IND Application Cleared to Begin Human Testing of - GlobeNewswire
Thu, 04 Apr 2024
Analysts Set Expectations for Imunon, Inc.'s Q1 2024 Earnings (NASDAQ:IMNN) - Defense World
Mon, 01 Apr 2024
Imunon, Inc. (NASDAQ:IMNN) Q4 2023 Earnings Call Transcript - Yahoo Finance
Thu, 28 Mar 2024
IMUNON Reports 2023 Financial Results and Provides Business Update - GlobeNewswire
Thu, 21 Mar 2024
IMUNON to Hold 2023 Financial Results and Business Update Conference Call on Thursday, March 28, 2024 - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 9 (M) |
| Shares Float | 9 (M) |
| Held by Insiders | 1.1 (%) |
| Held by Institutions | 4.4 (%) |
| Shares Short | 443 (K) |
| Shares Short P.Month | 491 (K) |
| EPS | -2.17 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.41 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -39.9 % |
| Return on Equity (ttm) | -91.4 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.22 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -19 (M) |
| Levered Free Cash Flow | -12 (M) |
| PE Ratio | -0.61 |
| PEG Ratio | 0 |
| Price to Book value | 0.92 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.65 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|